AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall

Retrieved on: 2024-02-02 18:21:42

Tags for this article:

Click the tags to see associated articles and topics

AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall. View article details on hiswai:

Excerpt

Neuroscience revenues increased 22.6% to $2.09 billion. Botox Therapeutic sales were $776 million, up 6.6%. Read Next: Botox And Similar ...

Article found on: finance.yahoo.com